[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"cognitive-symptom\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:cognitive-symptom":28},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,5,0,[8,45,76,117,144],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":4,"enrollmentInfo":19,"targetDuration":4,"studyType":22,"phases":23,"briefSummary":25,"conditions":26,"keywords":29,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":33,"lastUpdatePostDateStruct":34,"startDateStruct":37,"completionDateStruct":39,"leadSponsor":41,"locationsCount":44},"100518096","evaluation-of-impact-of-ai-assistance-on-workload-associated-w-preparation-of-rare-tumor-case-repts-100518096",false,"NCT06026098","Evaluation of Impact of AI Assistance on Workload Associated w Preparation of Rare Tumor Case Repts","A Prospective Evaluation of Impact of AI Assistance on Workload Associated With Preparation of Rare Tumor Case Reports","Inclusion Criteria:\n\n1\\. The subject is a physician, medical student, or postdoctoral student.\n\nExclusion Criteria:",true,"ALL","18 Years",{"count":20,"type":21},10,"ESTIMATED","INTERVENTIONAL",[24],"NA","The goal of this study is to explore cognitive burden perceptions among physicians in relation to case report writing. Furthermore, this study evaluates the use of artificial intelligence (AI) assistance as a tool to reduce cognitive burden among providers preparing and submitting case reports. If an AI-tool is helpful in this setting, it may potentially help increase reporting of rare medical events and thereby improve the evidence base for care of these patient populations. This study will occur at a single time point which is expected to last approximately 2 hours. This session will include reviewing two rare tumor cases and then writing a clinical vignette with and without AI assistance.",[27,28],"Cognitive Burden","Cognitive Symptom",[30,31],"artificial intelligence","case report","NOT_YET_RECRUITING","2026-06-22",{"date":35,"type":36},"2026-06-23","ACTUAL",{"date":38,"type":21},"2026-10",{"date":40,"type":21},"2026-12",{"name":42,"class":43},"UNC Lineberger Comprehensive Cancer Center","OTHER",1,{"id":46,"slug":47,"hasResults":11,"nctId":48,"briefTitle":49,"officialTitle":49,"acronym":50,"eligibilityCriteria":51,"healthyVolunteers":16,"sex":52,"minAge":53,"maxAge":54,"enrollmentInfo":55,"targetDuration":4,"studyType":22,"phases":57,"briefSummary":59,"conditions":60,"keywords":62,"overallStatus":32,"whyStopped":4,"lastUpdateSubmitDate":66,"lastUpdatePostDateStruct":67,"startDateStruct":69,"completionDateStruct":71,"leadSponsor":73,"locationsCount":75},"100640953","phase-2-jak-signaling-in-depression-and-cognition-in-male-football-players-100640953","NCT07608796","JAK Signaling in Depression and Cognition in Male Football Players","JAK DC in Play","Inclusion Criteria:\n\n* willing and able to give written informed consent\n* males\n* \\>10 years of playing football (at least 1 year in the NFL)\n* 40-55 years of age\n* Current Diagnostic and Statistical Manual (DSM)-V major depression or Bipolar, depressed type; or DSM-V major depression or Bipolar, depressed type in partial remission as diagnosed by the Structured Clinical Interview for the Diagnostic and Statistical Manual for Mental Disorders (SCID)-V\n* score of \\>10 on the PHQ-9 from screening and HAM-D score ≥16 for study entry\n* off all antidepressant or other psychotropic therapy (e.g., mood stabilizers, antipsychotics, and sedative hypnotics) for at least 4 weeks before baseline visit (8 weeks for fluoxetine) or on a stable psychotropic regimen for at least 4 weeks (and no planned changes)\n* CRP ≥3 mg\u002FL\n* PHQ-9 anhedonia (item #1) and cognitive (item #7) scores ≥2\n\nExclusion Criteria:\n\n* current or history of past autoimmune disorder\n* history or evidence (clinical or laboratory) of hepatitis B or C infection or human immunodeficiency virus infection\n* history of any type of cancer requiring treatment with more than minor surgery\n* unstable cardiovascular, endocrinologic, hematologic, hepatic, renal, or neurologic disease (as determined by physical examination, EKG, and laboratory testing)\n* significant hematological abnormalities at screening (ANC \\\u003C 1500, Hgb\\\u003C10, platelet\\\u003C 100,000)\n* history of progressive multifocal leukoencephalopathy\n* history of deep venous thrombosis\n* history of cardiovascular disease (coronary artery disease, congestive heart failure, stroke - controlled hypertension is OK)\n* major surgery within 6 months before screening, or will require major surgery during the study\n* current or recent (\\\u003C4 weeks before study start) viral (including COVID-19), bacterial, fungal, or parasitic infection, or any other active or recent infection\n* symptomatic herpes zoster infection at or within 12 weeks of study start\n* history of disseminated\u002Fcomplicated herpes zoster (for example, ophthalmic zoster or CNS involvement)\n* cirrhosis of the liver from any cause\n* Additional exclusion criteria apply","MALE","40 Years","55 Years",{"count":56,"type":21},30,[58],"PHASE2","This study is being done to learn more about the role of inflammation in depressive and cognitive symptoms in patients with depression who have played at least 10 years of organized football. This will be evaluated using a medication called baricitinib that blocks one aspect of inflammation.",[61,28],"Depressive Symptoms",[63,64,65],"Football player","Inflammation","NFL","2026-05-20",{"date":68,"type":36},"2026-05-27",{"date":70,"type":21},"2026-06",{"date":72,"type":21},"2027-10",{"name":74,"class":43},"Emory University",3,{"id":77,"slug":78,"hasResults":11,"nctId":79,"briefTitle":80,"officialTitle":81,"acronym":4,"eligibilityCriteria":82,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":84,"targetDuration":4,"studyType":22,"phases":86,"briefSummary":87,"conditions":88,"keywords":100,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":108,"lastUpdatePostDateStruct":109,"startDateStruct":111,"completionDateStruct":113,"leadSponsor":115,"locationsCount":44},"100521768","phase-2-personalized-brain-stimulation-to-treat-chronic-concussive-symptoms-100521768","NCT06073886","Personalized Brain Stimulation to Treat Chronic Concussive Symptoms","Personalized Circuit-Based Frontoamygdala Neuromodulation for Persistent Post-Concussive Symptoms","Inclusion Criteria:\n\n* Mild traumatic brain injury (mTBI) defined in accord with the World Health Organization criteria in the last 12 months\n* age 18-65 at the time of the mTBI\n* high burden of post-concussive symptoms defined as a score \\>=20 on the Rivermead Post-Concussion Symptoms Questionnaire\n\nExclusion Criteria:\n\n* objective neurologic deficits\n* ongoing or prolonged (\\>3 months) post-concussive symptoms from a prior mTBI within 2 years of the index injury\n* history of transcranial magnetic stimulation (TMS) therapy\n* contraindications for TMS or magnetic resonance imaging (MRI) (e.g., metallic implant other than dental, pacemaker)\n* severe mental, physical, or medical problems that would impede participation or pose a risk for the planned intervention (e.g., liver, kidney, or heart disease, uncontrolled diabetes or hypertension, malignancy, psychosis, previous seizure, pregnancy)\n* active alcohol or illicit drug abuse\n* inability to speak and read English","65 Years",{"count":85,"type":21},75,[58],"The goal of this study is to investigate a new treatment for chronic symptoms after concussion or mild traumatic brain injury in people aged 18-65 years old. Chronic symptoms could include dizziness, headache, fatigue, brain fog, memory difficulty, sleep disruption, irritability, or anxiety that occurred or worsened after the injury. These symptoms can interfere with daily functioning, causing difficulty returning to physical activity, work, or school. Previous concussion therapies have not been personalized nor involved direct treatments to the brain itself. The treatment being tested in the present study is a noninvasive, personalized form of brain stimulation, called transcranial magnetic stimulation (TMS).\n\nThe investigators intend to answer the questions:\n\n1. Does personalized TMS improve brain connectivity after concussion?\n2. Does personalized TMS improve avoidance behaviors and chronic concussive symptoms?\n3. Do the improvements last up to 2 months post-treatment?\n4. Are there predictors of treatment response, or who might respond the best?\n\nParticipants will undergo 14 total visits to University of California Los Angeles (UCLA):\n\n1. One for the baseline symptom assessments and magnetic resonance imaging (MRI)\n2. Ten for TMS administration\n3. Three for post-treatment symptom assessments and MRIs\n\nParticipants will have a 66% chance of being assigned to an active TMS group and 33% chance of being assigned to a sham, or inactive, TMS group. The difference is that the active TMS is more likely to cause functional changes in the brain than the inactive TMS.",[89,90,91,92,93,94,28,95,96,97,98,99],"Post-Concussion Syndrome","Concussion, Brain","Mild Traumatic Brain Injury","Head Injury","Headache","Dizziness","Dysautonomia","Anxiety","Irritability; Syndrome","Depression","Post-traumatic Stress Disorder",[101,102,103,104,105,106],"Transcranial Magnetic Stimulation","Magnetic Resonance Imaging","Functional MRI","Personalized neuromodulation","Amygdala","Prefrontal Cortex","RECRUITING","2026-02-21",{"date":110,"type":36},"2026-02-24",{"date":112,"type":36},"2024-03-06",{"date":114,"type":21},"2027-01",{"name":116,"class":43},"University of California, Los Angeles",{"id":118,"slug":119,"hasResults":11,"nctId":120,"briefTitle":121,"officialTitle":122,"acronym":123,"eligibilityCriteria":124,"healthyVolunteers":11,"sex":17,"minAge":18,"maxAge":125,"enrollmentInfo":126,"targetDuration":4,"studyType":22,"phases":128,"briefSummary":129,"conditions":130,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":135,"lastUpdatePostDateStruct":136,"startDateStruct":138,"completionDateStruct":140,"leadSponsor":142,"locationsCount":44},"100581271","using-non-invasive-brain-stimulation-to-treat-word-finding-difficulty-in-chronic-traumatic-brain-injury-100581271","NCT06848140","Using Non-invasive Brain Stimulation to Treat Word Finding Difficulty in Chronic Traumatic Brain Injury","Using High Definition Transcranial Direct Current Stimulation to Treat Verbal Retrieval Deficits Secondary to Chronic Traumatic Brain Injury (STIM-CTBI)","STIM-CTBI","Inclusion Criteria:\n\n* Age between 18 and 85\n* Fluent in speaking and reading English\n* Able to provide informed consent\n* Has a TBI at least one year prior to enrollment and not related to military experience\n* Has a confirmation of verbal retrieval difficulties as measured by the Verbal Retrieval Difficulty Interview questions\n\nExclusion Criteria:\n\n* Lifetime major or active neurologic conditions (e.g., stroke, epilepsy, brain tumor, dementia, seizure occurrence less than one year ago)\n* Lifetime major or active cardiovascular conditions (e.g., cardiac arrythmia, heart failure, heart attack)\n* Current substance use disorder\n* Lifetime major psychiatric disorders (e.g., schizophrenia, bipolar disorder)\n* Severe depression at the time of enrollment (BDI-II \\>= 29) or psychiatric ER visits or hospitalization less than 6 months ago prior to enrollment\n* Current sensory (e.g., blind, deaf) or physical (e.g., severe motor weakness) impairment that interferes with testing\n* Contraindications for tDCS or MRI\n* The person cannot be left alone for 8+ hours.\n* Not verbally communicative.\n* Currently undergoing and not wishing to discontinue speech and cognitive therapy during study participation.\n* Incapable of understanding the consent or unable to consent for oneself.\n* Unable to travel to BIDMC's Berenson-Allen Center\n* Pregnancy","85 Years",{"count":127,"type":21},24,[24],"The purpose of this study is to learn more about how brain stimulation affects word finding problems in people who have a traumatic brain injury (TBI). The type of brain stimulation used is called transcranial direct current stimulation (tDCS). tDCS delivers low levels of electric current to the brain and high definition tDCS (HD-tDCS) delivers the current with multiple electrodes on the scalp. This current is delivered with HD-tDCS to parts of the brain that may help with remembering things. The investigators hope that this can help to improve word finding and memory problems in people with TBI.",[131,132,28,133,134],"Traumatic Brain Injury","Word Finding Difficulty","Cognitive Change","Acquired Brain Injury","2025-10-19",{"date":137,"type":36},"2025-10-21",{"date":139,"type":36},"2025-10-01",{"date":141,"type":21},"2028-04-30",{"name":143,"class":43},"Beth Israel Deaconess Medical Center",{"id":145,"slug":146,"hasResults":11,"nctId":147,"briefTitle":148,"officialTitle":149,"acronym":150,"eligibilityCriteria":151,"healthyVolunteers":16,"sex":17,"minAge":18,"maxAge":83,"enrollmentInfo":152,"targetDuration":4,"studyType":154,"phases":4,"briefSummary":155,"conditions":156,"keywords":4,"overallStatus":107,"whyStopped":4,"lastUpdateSubmitDate":159,"lastUpdatePostDateStruct":160,"startDateStruct":162,"completionDateStruct":164,"leadSponsor":166,"locationsCount":44},"100542720","primecog-primary-care-cognitive-testing-100542720","NCT06346535","PrimeCog: Primary Care Cognitive Testing","PrimeCog: Cognitive Profile, Psychosocial Characteristics, Brain MRI and Biomarkers for Stress and Neurodegeneration in Patients With Depression or Stress Induced Exhaustion Disorder in Primary Care.","PrimeCog","Inclusion Criteria:\n\n1. adults 18 to 65 years old;\n2. fluent in Swedish;\n3. corrected to normal vision and hearing;\n4. (for cases), newly diagnosed with MDD or SED (i.e., received as new diagnosis at the visit to the physician) according to the diagnostic criteria from DSM-V (MDD) and the Swedish Board of Health and Welfare (SED)\n\nExclusion Criteria:\n\n1. already ongoing treatment for MDD\u002FSED or previous diagnosis of MDD\u002FSED within the last year;\n2. history of serious mental illness (defined as mental illness that has required psychiatric in-patient care);\n3. acute cerebrovascular event or severe head trauma in the last 6 months;\n4. known cognitive impairment;\n5. substance dependence, ongoing or past;\n6. motor disability or impairment affecting interaction with the digital tests;\n7. photosensitive epilepsy or -migraines.\n\nFor the MRI subgroup, any contraindication to MRI is an exclusion criterion.",{"count":153,"type":21},300,"OBSERVATIONAL","The PrimeCog study aims to describe the symptomatology and pathophysiology of stress-induced exhaustion disorder (SED) and major depressive disorder (MDD) compared to healthy controls (HC). The participants will be recruited at primary care centers, and samples of blood, saliva, and hair will be collected. Digital questionnaires covering psychosocial variables and screening instruments for the detection of depression, anxiety, etc., along with a digital cognitive test battery, will be performed at home. Subsequently, an MRI of the brain will be performed, and analysis of biomarkers for stress, inflammation, and neurodegeneration will be conducted. These procedures will be repeated after twelve and twenty-four months. The study will investigate differences in the biomarkers, neuroimaging findings, and cognitive abilities between patients with SED, MDD, and controls over time. Associations between the symptom severity of MDD\u002FSED and psychosocial variables, cognition, MRI, and the biomarkers will also be examined. The aim is to provide new diagnostic tools for differentiation between MDD and SED and guide individualized treatment based on underlying pathophysiology and cognitive function. All necessary competences for conducting this extensive study are represented within the research group. The PrimeCog study is unique in its comprehensive design, addressing knowledge gaps, and directly comparing these diagnoses over time in primary care, where patients are typically treated.",[157,28,158],"Mental Health Issue","Primary Health Care","2024-04-19",{"date":161,"type":36},"2024-04-23",{"date":163,"type":36},"2024-04-01",{"date":165,"type":21},"2029-04-01",{"name":167,"class":43},"Region Östergötland"]